77P A study to evaluate the safety, tolerability and efficacy of IBI939 in combination with sintilimab in patients with previously untreated locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). (December 2022) - Cheng, Y.; Liu, B.; Wu, L.; Zhang, T.; Wang, K.; L. Miao,; Wu, J.; Wang, H.; Fang, J.; Li, X.; Zhang, W.; Hu, Y.; et al.